

IDS 9/20/2006

Sheet 1 of 1

Based on Form PTO-1449 (3/90) LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)			ATTY. DOCKET NO.		SERIAL NO.		
			516745-2001.1		10/611,539		
			APPLICANT				
			Lal et al				
FILING DATE			GROUP				
July 1, 2003			1626				
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AB						YES NO
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
JK	AC		Schwartz et al, "Phase I Study of Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination with Paclitaxel in Patients with Advanced Solid Tumors", Journal of Clinical Oncology, Vol. 20, No. 8, April 15, 2002, pp. 2157-2170;				
JK	AD		Tan et al, "Phase I Clinical and Pharmacokinetic Study of Flavopiridol Administered as a Daily 1-Hour Infusion in Patients with Advanced Neoplasms", Journal of Clinical Oncology, Vol. 20, No. 19, October 1, 2002, pp. 4074-4082;				
JK	AE		Hirama et al, BLOOD, "Role of the Cyclin-Dependent Kinase Inhibitors in the Development of Cancer", The Journal of The American Society of Hematology, August 1, 1995, Blood, Vol. 88, No. 3, August 1, 1995, pp. 841-854;				
JK	AF		Edward A. Sausville, "Cyclin-Dependent Kinases: Novel Targets for Cancer Treatment", Developmental Therapeutics Program, pp. 9-21;				
JK	AG		Elsayed et al, "Selected Novel Anticancer Treatments Targeting Cell Signaling Proteins", <i>The Oncologist</i> , 2001; 6: pp. 517-537;				
JK	AH		Meier et al, "Properties and Potential Applications of Chemical Inhibitors of Cyclin-Dependent Kinases", Pharmacol, Ther., Vol 82, Nos., 2-3, pp. 279-284, 1999;				
JK	AI		Sausville et al, "Cyclin-Dependent Kinases: Initial Approaches to Exploit a Novel Therapeutic Target", Pharmacol, Ther. Vol. 82, Nos. 2-3, pp. 285-292, 1999;				
JK	AJ		Parker et al, "Early Induction of Apoptosis in Hematopoietic Cells Lines After Exposure to Flavopiridol", The American Society of Hematology, Blood, Vol. 91, No. 2, January 15, 1998; pp. 458-465.				
EXAMINER			DATE CONSIDERED				
/Joseph Kosack/			01/12/2007				
* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

00398450